Dr Roger Thompson
MB ChB BSc MRCP(UK) PhD
Clinical Medicine, School of Medicine and Population Health
Senior Clinical Lecturer in Respiratory Medicine
Honorary Consultant in Respiratory Medicine
+44 114 215 9558
Full contact details
Clinical Medicine, School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX
- Profile
-
For enquiries please contact - ClinMed-Operational@sheffield.ac.uk
I moved to Sheffield in 2006 to take up an NIHR Academic Clinical Fellowship in Respiratory Medicine having completed my undergraduate training and a medical rotation in Edinburgh. I completed an MRC Training Fellowship and PhD in 2012 under the supervision of Professor Moira Whyte and Dr Sarah Walmsley before finishing my specialist clinical training as an NIHR Clinical Lecturer.
In 2016, I was appointed as a JG Graves Fellow and an Honorary Consultant in Respiratory Medicine at Sheffield Teaching Hospitals NHS Foundation Trust. For 12 months from September 2017 I was a BHF-Fulbright scholar (www.fulbright.org.uk) in Professor Marlene Rabinovitch’s lab at Stanford University and returned to Sheffield in 2018 as a BHF Intermediate Clinical Fellow. I am now a Senior Clinical Lecturer in Respiratory Medicine.
- Research interests
-
Hypoxia has been the general theme of my research interests. In 2001 and 2003 I organised two successful high altitude research expeditions to Bolivia, focusing on maladaptive responses to hypoxia that can result in altitude illness (www.altitude.org). During my PhD, I broadened my interests into the field of cell biology, specifically the role of HIF-2alpha in neutrophilic inflammation. I also worked on host pathogen interactions in hypoxia and demonstrated that ambient hypoxia adversely altered the host response to a limited bacterial challenge, provoking a profound phenotype of systemic illness including cardiovascular dysfunction.
Aligning my research interests with my clinical interest in pulmonary arterial hypertension (a devastating disease characterised by progressive remodelling of pulmonary blood vessels), my postdoctoral research has focussed on the role of inflammation and hypoxia in this condition. In collaboration with Laszlo Farkas (VCU), we showed that deficiency of the pattern recognition receptor (TLR3) exacerbated pulmonary hypertension, while activating TLR3 (using synthetic double-stranded RNA) reduced the severity of pulmonary hypertension in animal models of the disease. Current work aims to dissect the mechanisms by which double-stranded RNA regulates pulmonary vascular remodelling.
During the Covid-19 pandemic, I became interested in the clinical application of advanced imaging techniques for lung disease, and I participated in several multi-centre studies investigating the mechanisms of breathlessness in post-Covid patients. In ongoing work with the POLARIS group, the potential role of this technology in pulmonary vascular diseases will be explored.
Current projects
- Hypoxic modulation of host responses to infection.
- Regulation of pulmonary vascular remodelling by endogenous double stranded RNA.
- Multinuclear MR imaging to phenotype pulmonary vascular diseases.
- STH Observational Study of Patients with Pulmonary Hypertension, Cardiovascular and other Respiratory Diseases (STH-ObS) (Research Tissue Bank, Chief Investigator).
- Publications
-
Show: Featured publications All publications
Featured publications
Journal articles
- Age, sex, and lung volume dependence of dissolved xenon‐129 MRI gas exchange metrics. Magnetic Resonance in Medicine. View this article in WRRO
- Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), 607-621. View this article in WRRO
- Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. European Respiratory Journal, 63(3). View this article in WRRO
- Mendelian Randomization Study With Clinical Follow‐Up Links Metabolites to Risk and Severity of Pulmonary Arterial Hypertension. Journal of the American Heart Association, 13(6).
- Unsupervised machine learning to investigate trajectory patterns of COVID-19 symptoms and physical activity measured via the MyHeart Counts App and smart devices. npj Digital Medicine, 6. View this article in WRRO
- Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal, 62(2). View this article in WRRO
- Longitudinal lung function assessment of patients hospitalised with COVID-19 using 1H and 129Xe lung MRI. Chest.
- A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3. iScience, 26(2).
- Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine. View this article in WRRO
- Phenotyping of idiopathic pulmonary arterial hypertension : a registry analysis. The Lancet Respiratory Medicine.
- Endogenous retroviral elements generate pathologic neutrophils in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine.
- Soluble P-selectin and von Willebrand factor rise in healthy volunteers following non-exertional ascent to high altitude. Frontiers in Physiology, 13.
- Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12. View this article in WRRO
- Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. The Lancet, 398(10296), 223-237. View this article in WRRO
- Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension.. Arteriosclerosis, thrombosis, and vascular biology, 41(1), 430-445. View this article in WRRO
- Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension.. The European respiratory journal, 55(6). View this article in WRRO
- RNA signaling in pulmonary arterial hypertension-a double-stranded sword. International Journal of Molecular Sciences, 21(9). View this article in WRRO
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
- Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.. Elife, 8. View this article in WRRO
- Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. Frontiers in Medicine, 6. View this article in WRRO
- Toll-like receptor 3 is a therapeutic target for pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 199(2). View this article in WRRO
- The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. Frontiers in Medicine, 5. View this article in WRRO
- Hypoxia determines survival outcomes of bacterial infection through HIF-1α-dependent reprogramming of leukocyte metabolism. Science Immunology, 2(8). View this article in WRRO
- Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends in Molecular Medicine, 23(1), 31-45. View this article in WRRO
- MET is required for the recruitment of anti-tumoural neutrophils. Nature, 522(7556), 349-353. View this article in WRRO
- Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. Blood, 123(3), 366-376.
All publications
Journal articles
- Mapping the amplitude and phase of dissolved
129Xe red blood cell signal oscillations with keyhole spectroscopic lung imaging. Magnetic Resonance in Medicine. - The spectrum of systemic sclerosis-associated pulmonary hypertension: Insights from the ASPIRE registry. The Journal of Heart and Lung Transplantation, 43(10), 1629-1639.
- Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. The Lancet Psychiatry.
- CTEPH is an uncommon complication of COVID-19: UK national surveillance and observational screening cohort studies. European Respiratory Journal, 2301742-2301742.
- Association of risk assessment at diagnosis with healthcare resource utilization and health‐related quality of life outcomes in pulmonary arterial hypertension. Pulmonary Circulation, 14(3). View this article in WRRO
- Age, sex, and lung volume dependence of dissolved xenon‐129 MRI gas exchange metrics. Magnetic Resonance in Medicine. View this article in WRRO
- Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25(4), 607-621. View this article in WRRO
- Long-term impact of COVID-19 hospitalisation among individuals with pre-existing airway diseases in the UK: a multicentre, longitudinal cohort study – PHOSP-COVID. ERJ Open Research, 10(4), 00982-2023.
- Pulmonary hypertension: intensification and personalization of combination Rx (PHoenix): a phase IV randomized trial for the evaluation of dose‐response and clinical efficacy of riociguat and selexipag using implanted technologies. Pulmonary Circulation, 14(1). View this article in WRRO
- Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry. European Respiratory Journal, 63(3). View this article in WRRO
- Mendelian Randomization Study With Clinical Follow‐Up Links Metabolites to Risk and Severity of Pulmonary Arterial Hypertension. Journal of the American Heart Association, 13(6).
- Improving Prognostication in Pulmonary Hypertension Using AI-quantified Fibrosis and Radiologic Severity Scoring at Baseline CT. Radiology, 310(2).
- Accelarated immune ageing is associated with COVID-19 disease severity. Immunity & Ageing, 21. View this article in WRRO
- Risk assessment and real-world outcomes in chronic thromboembolic pulmonary hypertension: insights from a UK pulmonary hypertension referral service. BMJ Open, 14(1). View this article in WRRO
- Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. Brain Communications, 6(1).
- Unsupervised machine learning to investigate trajectory patterns of COVID-19 symptoms and physical activity measured via the MyHeart Counts App and smart devices. npj Digital Medicine, 6. View this article in WRRO
- Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14(1), 8487.
- Long COVID research: an update from the PHOSP-COVID Scientific Summit. The Lancet Respiratory Medicine, 11(11), e93-e94.
- Multiorgan MRI findings after hospitalisation with COVID-19 in the UK (C-MORE): a prospective, multicentre, observational cohort study. The Lancet Respiratory Medicine.
- Establishing minimally important differences for cardiac MRI end-points in pulmonary arterial hypertension. European Respiratory Journal, 62(2). View this article in WRRO
- Determinants of recovery from post-COVID-19 dyspnoea: analysis of UK prospective cohorts of hospitalised COVID-19 patients and community-based controls. The Lancet Regional Health - Europe, 100635-100635.
- Non-invasive detection of severe PH in lung disease using magnetic resonance imaging. Frontiers in Cardiovascular Medicine, 10.
- Effects of sleep disturbance on dyspnoea and impaired lung function following hospital admission due to COVID-19 in the UK: a prospective multicentre cohort study. The Lancet Respiratory Medicine.
- Longitudinal lung function assessment of patients hospitalised with COVID-19 using 1H and 129Xe lung MRI. Chest.
- Prevalence of physical frailty, including risk factors, up to 1 year after hospitalisation for COVID-19 in the UK: a multicentre, longitudinal cohort study. eClinicalMedicine, 57, 101896-101896.
- Implementable deep learning for multi-sequence proton MRI lung segmentation: a multi-center, multi-vendor, and multi-disease study. Journal of Magnetic Resonance Imaging.
- A p53-TLR3 axis ameliorates pulmonary hypertension by inducing BMPR2 via IRF3. iScience, 26(2).
- SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87.
- Residual lung abnormalities following COVID-19 hospitalization: interim analysis of the UKILD post-COVID study. American Journal of Respiratory and Critical Care Medicine, 207(6), 693-703. View this article in WRRO
- Strengthening altitude knowledge: a delphi study to define minimum knowledge of altitude illness for laypersons traveling to high altitude. High Altitude Medicine and Biology.
- Atrial flutter and fibrillation in patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension in the ASPIRE registry: comparison of rate versus rhythm control approaches. International Journal of Cardiology.
- Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial. The Lancet Respiratory Medicine. View this article in WRRO
- First genotype-phenotype study in TBX4 syndrome : gain-of-function mutations causative for lung disease. American Journal of Respiratory and Critical Care Medicine.
- Big data and long COVID. The Lancet Digital Health, 4(7), e477-e477.
- Phenotyping of idiopathic pulmonary arterial hypertension : a registry analysis. The Lancet Respiratory Medicine.
- Endogenous retroviral elements generate pathologic neutrophils in pulmonary arterial hypertension. American Journal of Respiratory and Critical Care Medicine.
- Lung abnormalities depicted with hyperpolarized Xenon MRI in patients with Long COVID. Radiology, 305(3).
- Right ventricular remodelling in pulmonary arterial hypertension predicts treatment response.. Heart, 108, 1392-1400.
- Procalcitonin is not a reliable biomarker of bacterial coinfection in people with coronavirus disease 2019 undergoing microbiological investigation at the time of hospital admission. Open Forum Infectious Diseases, 9(5).
- Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. The Lancet Respiratory Medicine.
- Severe pulmonary hypertension associated with lung disease is characterised by a loss of small pulmonary vessels on quantitative CT. ERJ Open Research.
- Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the protein kinase C inhibitor ruboxistaurin. ERJ Open Research, 8(2). View this article in WRRO
- Imaging and risk stratification in pulmonary arterial hypertension : time to include right ventricular assessment. Frontiers in Cardiovascular Medicine, 9.
- Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. The Lancet Digital Health, 4(4), e220-e234.
- Soluble P-selectin and von Willebrand factor rise in healthy volunteers following non-exertional ascent to high altitude. Frontiers in Physiology, 13.
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 185(3), 467-484.e15.
- Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study : a prospective, multicentre cohort study. Nephrology Dialysis Transplantation, 37(2), 271-284.
- Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19. Heart.
- Biological heterogeneity in idiopathic pulmonary arterial hypertension identified through unsupervised transcriptomic profiling of whole blood. Nature Communications, 12. View this article in WRRO
- The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. iScience, 24(11). View this article in WRRO
- Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors : a cross-sectional study. BMJ Open, 11(10).
- Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study.. The Lancet Respiratory Medicine.
- COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study. Infection, 49(5), 889-905.
- A prenylated dsRNA sensor protects against severe COVID-19. Science.
- Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respiratory Research, 8(1).
- Pulmonary hypertension phenotypes in patients with systemic sclerosis. European Respiratory Review, 30(161), 210053-210053.
- Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. The Lancet, 398(10296), 223-237. View this article in WRRO
- Mapping the human genetic architecture of COVID-19. Nature, 600(7889), 472-477. View this article in WRRO
- A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach. EBioMedicine, 69, 103444-103444.
- Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC Health Services Research, 21. View this article in WRRO
- Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study : a multicentre, prospective cohort study. The Lancet Microbe. View this article in WRRO
- Going viral: misinformation in the time of COVID-19. The Lancet Rheumatology, 3(6), e393-e393.
- Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. The Lancet Respiratory Medicine.
- Cardiovascular magnetic resonance predicts all-cause mortality in pulmonary hypertension associated with heart failure with preserved ejection fraction. International Journal of Cardiovascular Imaging.
- Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. The Lancet Rheumatology. View this article in WRRO
- Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 : a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. The Lancet Respiratory Medicine.
- Neutrophils fuel effective immune responses through gluconeogenesis and glycogenesis. Cell Metabolism, 33(2), 411-423.e4.
- Development and validation of the ISARIC 4C deterioration model for adults hospitalised with COVID-19: a prospective cohort study. The Lancet Respiratory Medicine.
- Altered macrophage polarization induces experimental pulmonary hypertension and is observed in patients with pulmonary arterial hypertension.. Arteriosclerosis, thrombosis, and vascular biology, 41(1), 430-445. View this article in WRRO
- Genetic mechanisms of critical illness in Covid-19. Nature.
- Right ventricular adaptation assessed using cardiac magnetic resonance predicts survival in pulmonary arterial hypertension. JACC: Cardiovascular Imaging.
- Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study. American Journal of Respiratory and Critical Care Medicine, 202(12), 1656-1665. View this article in WRRO
- Maximal exercise testing using the incremental shuttle walking test can be used to risk stratify patients with pulmonary arterial hypertension. Annals of the American Thoracic Society.
- Whole Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine, 0(ja), 586-594.
- When Innate Immunity Meets Angiogenesis-The Role of Toll-Like Receptors in Endothelial Cells and Pulmonary Hypertension.. Frontiers in medicine, 7, 352.
- EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study. European Respiratory Journal. View this article in WRRO
- Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension.. The European respiratory journal, 55(6). View this article in WRRO
- RNA signaling in pulmonary arterial hypertension-a double-stranded sword. International Journal of Molecular Sciences, 21(9). View this article in WRRO
- Partial anomalous pulmonary venous drainage in patients presenting with suspected pulmonary hypertension: A series of 90 patients from the ASPIRE registry. Respirology. View this article in WRRO
- Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 201(4), 458-468.
- Exploring patients’ experience and perception of being diagnosed with bladder cancer: a mixed-methods approach. BJU International, 125(5), 669-678.
- Hypoxia Modulates Platelet Purinergic Signalling Pathways. Thrombosis and Haemostasis, 120(02), 253-261.
- A therapeutic antibody targeting osteoprotegerin attenuates severe experimental pulmonary arterial hypertension. Nature Communications, 10(1). View this article in WRRO
- Inhibition of ErbB kinase signalling promotes resolution of neutrophilic inflammation.. Elife, 8. View this article in WRRO
- Thin Air, Thick Vessels: Historical and Current Perspectives on Hypoxic Pulmonary Hypertension. Frontiers in Medicine, 6. View this article in WRRO
- Express: The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.. Pulmonary Circulation. View this article in WRRO
- Toll-like receptor 3 is a therapeutic target for pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 199(2). View this article in WRRO
- The impact of patient choice on survival in chronic thromboembolic pulmonary hypertension. European Respiratory Journal, 52(3). View this article in WRRO
- The Role of Neutrophils and Neutrophil Elastase in Pulmonary Arterial Hypertension. Frontiers in Medicine, 5. View this article in WRRO
- The 2018 Lake Louise Acute Mountain Sickness Score. High Altitude Medicine & Biology, 19(1), 4-6.
- Thromboelastometry and Platelet Function during Acclimatization to High Altitude. Thrombosis and Haemostasis, 118(01), 063-071.
- Selective improvement of pulmonary arterial hypertension with a dual ET A /ET B receptors antagonist in the apolipoprotein E −/− model of PAH and atherosclerosis. Pulmonary Circulation, 8(1), 1-11. View this article in WRRO
- Mechanical Activation of Hypoxia-Inducible Factor 1α Drives Endothelial Dysfunction at Atheroprone Sites.. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(11), 2087-2101. View this article in WRRO
- Prolyl hydroxylase 2 inactivation enhances glycogen storage and promotes excessive neutrophilic responses.. Journal of Clinical Investigation, 127(9), 3407-3420. View this article in WRRO
- Hypoxia determines survival outcomes of bacterial infection through HIF-1α-dependent reprogramming of leukocyte metabolism. Science Immunology, 2(8). View this article in WRRO
- Targeting Vascular Remodeling to Treat Pulmonary Arterial Hypertension. Trends in Molecular Medicine, 23(1), 31-45. View this article in WRRO
- Hypoxic regulation of neutrophil function and consequences for Staphylococcus aureus infection. Microbes and Infection. View this article in WRRO
- Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension. European Respiratory Journal, 48(5), 1514-1514.
- Mutations in succinate dehydrogenase B (SDHB) enhance neutrophil survival independent of HIF-1α expression. Blood, 127(21), 2641-2644. View this article in WRRO
- MET is required for the recruitment of anti-tumoural neutrophils. Nature, 522(7556), 349-353. View this article in WRRO
- A local circadian clock calls time on lung inflammation. Nature Medicine, 20(8), 809-811.
- Network analysis reveals distinct clinical syndromes underlying acute mountain sickness.. PloS one, 9(1), e81229. View this article in WRRO
- Hypoxia-inducible factor 2α regulates key neutrophil functions in humans, mice, and zebrafish. Blood, 123(3), 366-376.
- Hypoxia, the HIF pathway and neutrophilic inflammatory responses. Biological Chemistry, 394(4), 471-477.
- Retinal Vessel Tortuosity in Response to Hypobaric Hypoxia. HIGH ALTITUDE MEDICINE & BIOLOGY, 13(4), 263-268.
- A decoy receptor 3 analogue reduces localised defects in phagocyte function in pneumococcal pneumonia. Thorax, 67(11), 985-992. View this article in WRRO
- Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis. Thorax, 67(9), 796-803. View this article in WRRO
- Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice. Journal of Clinical Investigation, 121(3), 1053-1063. View this article in WRRO
- Prolyl Hydroxylase Phd3 Is Essential For Hypoxic Regulation Of Neutrophilic Inflammation. C13. PATHOGENESIS OF ACUTE LUNG INJURY.
- Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: Double blind, randomized, placebo-controlled trial. High Altitude Medicine and Biology, 12(3), 207-214.
- Hypoxia selectively inhibits respiratory burst activity and killing of Staphylococcus aureus in human neutrophils. Journal of Immunology, 186(1), 453-463.
- Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro.. High Alt Med Biol, 11(3), 217-222.
- A complication of peroral bronchoscopy. EUR RESPIR J, 35(1), 221-222.
- The citric acid cough threshold and the ventilatory response to carbon dioxide on ascent to high altitude.. Respir Med, 103(8), 1182-1188.
- Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial.. QJM, 102(5), 341-348.
- NT-proBNP Does Not Rise on Acute Ascent to High Altitude. HIGH ALT MED BIOL, 9(4), 307-310.
- Manual Assessment of the Initial Fall in Blood Pressure After Orthostatic Challenge at High Altitude. WILD ENVIRON MED, 19(4), 225-232.
- Endogenous urate production augments plasma antioxidant capacity in healthy lowland subjects exposed to high altitude.. Chest, 131(5), 1473-1478.
- Phosphodiesterase type 5 inhibitors in the treatment and prevention of high altitude pulmonary edema. CURR OPIN INVESTIG D, 8(3), 226-231.
- Change in plasma vascular endothelial growth factor during onset and recovery from acute mountain sickness.. Respir Med, 101(3), 587-594.
- Catastrophe for a campanologist.. Eur J Emerg Med, 13(3), 184-186.
- Pericardial effusions in healthy lowlanders after acute ascent to high altitude. HEART, 92(4), 539-540.
- Endothelial nitric oxide synthase polymorphisms do not influence pulmonary artery systolic pressure at altitude. HIGH ALT MED BIOL, 7(3), 221-227.
- Do Hemodynamic Definitions of Chronic Thromboembolic Pulmonary Hypertension Distinguish Between Distinct Phenotypes of Chronic Thromboembolic Pulmonary Disease?. Annals of the American Thoracic Society.
- One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study. ERJ Open Research, 00474-2024.
- A serum calprotectin lateral flow test as an inflammatory and prognostic marker in acute lung infection: a prospective observational study. ERJ Open Research, 00059-02024.
- Cohort Profile: Post-Hospitalisation COVID-19 (PHOSP-COVID) study. International Journal of Epidemiology.
- Quantifying neutralising antibody responses against SARS-CoV-2 in dried blood spots (DBS) and paired sera. Scientific Reports, 13(1).
- Elective lower limb orthopaedic arthroplasty surgery in patients with pulmonary hypertension. Pulmonary Circulation.
- Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I. Frontiers in Medicine, 5. View this article in WRRO
- HIF-mediated innate immune responses: cell signaling and therapeutic implications. Hypoxia, 47-47. View this article in WRRO
- Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. ERJ Open Research, 00046-2021.
- Editorial : pulmonary hypertension : mechanisms and management, history and future. Frontiers in Medicine, 7. View this article in WRRO
Conference proceedings papers
- PKR Activation Caused by ADAR1 Deficeincy Contributes to Vascular Remodeling in PAH. D95. SURVEYING THE ZOO: -OMICS FOR MECHANISTIC DISCOVERY IN PULMONARY VASCULAR DISEASE
- S81 Assessment of endothelial function in Long-COVID and in patients with residual lung abnormalities after COVID-19. ‘Bad blood’ – Biomarkers and mechanisms in long COVID
- S20 Long-COVID: a multi-faceted syndrome explored in the EXPLAIN study (HypErpolarised xenon magnetic resonance PuLmonary ImAging In PatieNts with Long-COVID). ‘Shake it off’ – Recovery from COVID-19
- S19 Gas exchange imaging using dissolved-phase 129Xe MRI in post COVID cohorts. ‘Shake it off’ – Recovery from COVID-19
- Impaired xenon gas transfer observed two years after COVID-19 hospitalisation in patients with signs of interstitial lung disease. Imaging
- Evaluating the utility of a serum calprotectin lateral flow test in acute lung infection. Respiratory infections and bronchiectasis
- Age, sex and lung volume dependence of 129Xe MRI gas exchange metrics. Clinical respiratory physiology, exercise and functional imaging
- Unexplained lung function differences in dyspnoeic non-hospitalised Long-COVID (NHLC) patients and asymptomatic fully recovered COVID-19 controls - the EXPLAIN study. Clinical respiratory physiology, exercise and functional imaging (pp PA1180-PA1180)
- Artificial Intelligence and Computed Tomography to improve quantification and prognostication of lung disease in precapillary pulmonary hypertension. Pulmonary hypertension (pp PA3490-PA3490)
- 155 Effect of covid-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. Heart Failure
- 137 Design and validation of a physiological risk score for pulmonary arterial hypertension (pah). Heart Failure
- 138 Physiological detection of clinical worsening and therapeutic response using implanted remote technologies in pah. Heart Failure
- 153 Differences in physical activity, heart rate and heart variability during clinical worsening events in patients with pulmonary arterial hypertension (pah). Heart Failure
- 154 Stability of daily physical activity as a remote measure of clinical risk in pulmonary arterial hypertension (pah). Heart Failure
- 158 Remote personalisation of pulmonary arterial hypertension therapy and application of a remote physiological risk score. Heart Failure
- 196 The relationship of physical activity, heart rate variability, and night heart rate to established measures of clinical risk in patients with pulmonary arterial hypertension (pah). Stable IHD/Prevention/Hypertension/Lipids
- BS74 Assessment of fluid status in porcine models of heart failure and pulmonary hypertension. Basic Science
- Osteoprotegerin Has Distinct Roles in Pulmonary Vascular and Cardiac Remodelling in a Mouse Model of Pulmonary Arterial Hypertension. A14. THIS IS GETTING COMPLICATED: EPIGENETICS, -OMICS, AND CELL SIGNALING IN PULMONARY HYPERTENSION
- Unpicking the Effects of General Control Non-depressible 2 (GCN2) Deficiency in Pulmonary Veno-Occlusive Disease. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
- Systematic Follow-up of Patients Following Acute Pulmonary Embolism Identifies High Incidence of Chronic Thromboembolic Pulmonary Hypertension: ASPIRE CTEPH. D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE
- Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH (REPEAT-PAH). B57. INTERMEDIATES, CORRELATES, AND SURROGATES, OH MY!: NOVEL END POINTS AND ASSESSMENTS IN PVD
- ADAR1 Mediated RNA Editing Contributes to Vascular Remodeling in PAH. D18. MOLECULAR TRAFFIC HUBS IN PULMONARY VASCULAR DISEASE
- Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial. 10.01 - Respiratory infections and bronchiectasis
- The effect of parenchymal lung disease on patient characteristics and outcome in SSc-PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- New diagnostic criteria and PVR thresholds in SSc-associated PH: Insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. 13.01 - Pulmonary hypertension
- P169 Non-generalisability of biomarkers for mortality in SARS-CoV-2. ‘Infinity War’ – Ongoing clinical challenges in COVID-19
- P81 Effect of COVID-19 infection and preventive public health measures on haemodynamics, activity and quality of life in patients with pulmonary arterial hypertension. ‘Contagion’ – The impact of COVID-19
- S92 Remote monitoring enabled evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- P37 Correlation of emPHasis-10 with clinical tests: insights from the ASPIRE registry. ‘Mission (Im)possible I’ – Pulmonary vascular disease
- S91 Remote monitored physical activity is related to established measures of clinical risk in patients with pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- S90 Right ventricular remodelling assessed using cardiac magnetic resonance predicts survival and treatment response in pulmonary arterial hypertension. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- S93 Systematic follow-up of patients following acute pulmonary embolism is associated with an increased incidence of chronic thromboembolic pulmonary hypertension and less severe disease. ‘The Sixth Sense’ – Prognostication in pulmonary vascular disease
- P38 Assessing the repeatability of NT-proBNP testing using laboratory and point of care testing in PAH (REPEAT-PAH). ‘Mission (Im)possible I’ – Pulmonary vascular disease
- Abstract 13553: Remote Monitoring of the Haemodynamic Response to Clinically Indicated Therapeutic Escalation and Clinical Worsening Events in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13553-a13553)
- Abstract 13527: The Development of a Remote Pulmonary Arterial Hypertension Risk Score Utilising Remote Monitoring Technology to Monitor Parameters Associated With Mortality in Pulmonary Arterial Hypertension. Circulation, Vol. 146(Suppl_1) (pp a13527-a13527)
- Abstract 10848: Adar1 Mediated Rna Editing Contributes to Vascular Remodeling. Circulation, Vol. 146(Suppl_1) (pp a10848-a10848)
- Lung Subtraction Iodine Mapping in Breathless Patients After COVID-19. C30. LIFE AND LUNGS AFTER COVID: FUNCTIONAL RECOVERY AND OUTCOMES FOLLOWING SARS-CoV2 INFECTION (pp a3914-a3914)
- Transcriptomic Changes in Hospitalised COVID19 Patients Across 29 Days Provide Insight into the Systemic Immune Response and Disease Outcomes: Results from PREDICT-COVID19. D17. TOP KNOWLEDGE IN COVID (pp a5050-a5050)
- A Randomized Double-Blind Placebo-Controlled Trial of Dipeptidyl Peptidase-1 Inhibition in Hospitalized Patients with COVID-19: The STOP-COVID19 Trial. D17. TOP KNOWLEDGE IN COVID (pp a5055-a5055)
- Unsupervised Clustering of PH Using Circulating miRNA - Towards Molecular Classification of PH?. B96. FISHERMAN'S WHARF: OMICS AND TRANSLATIONAL APPROACHES IN PULMONARY VASCULAR DISEASE (pp a3440-a3440)
- Longitudinal Analysis of Three Major Risk-Associated Transcriptomic Subgroups Within the IPAH Classification. C55. NOB HILL: CELLULAR ORIGINS OF PULMONARY VASCULAR DISEASE (pp a4432-a4432)
- Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry. Pulmonary hypertension
- Abstract 13581: Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. Circulation, Vol. 144(Suppl_1)
- 121 Effect of UK COVID-19 public health measures on activity and quality of life in patients with pulmonary arterial hypertension. Heart failure
- P140 Comparison of different measures of diffusion capacity in suspected systemic sclerosis associated pulmonary arterial hypertension. The nuts and bolts of ILD clinical management
- Heart Rhythm versus Heart Rate Control Strategy in Patients With Pre-Capillary Pulmonary Hypertension and Atrial Arrhythmias. CIRCULATION, Vol. 144
- Abstract 15636: Effect of COVID-19 Public Health Measures on Activity and Quality of Life in Patients With Pulmonary Arterial Hypertension. Circulation, Vol. 142(Suppl_3) View this article in WRRO
- Percent-predicted incremental shuttle walking test distance stratifies risk in pulmonary arterial hypertension. Pulmonary hypertension
- Mild parenchymal lung disease and/or low diffusion capacity impacts survival and treatment response in patients diagnosed with idiopathic pulmonary arterial hypertension. Pulmonary hypertension
- EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study. Pulmonary hypertension
- The Anti-Osteoprotegerin (OPG) Antibody Ky3 Attenuates OPG-Fas Mediated Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Pro-Inflammatory Signalling In Vitro and In Vivo. A107. BYSTANDERS NO MORE: INFLAMMATION, IMMUNITY AND THROMBOSIS IN PULMONARY VASCULAR AND LUNG DISEASE
- Cardiac MRI: Identifying Thresholds to Predict Mortality in Pulmonary Arterial Hypertension. B27. HEARTBREAKER: HEART FAILURE AND PULMONARY HYPERTENSION
- The Incremental Shuttle Walking Test Can Be Used to Risk Stratify Patients with Pulmonary Hypertension as Per the European Respiratory/Cardiac Society Guidelines. A105. GLORY DAYS: THE LATEST CLINICAL RESEARCH IN PAH
- Homeostatic Role for the P53-Dependent Toll-Like Receptor 3 Expression in the Pulmonary Endothelium. A97. STATION TO STATION: UNRAVELING THE MOLECULAR PATHOGENESIS OF PAH
- T6 Vascular smooth muscle derived TRAIL underlies pulmonary vascular remodelling in sugen 5416/hypoxia mice. BTS/BALR/BLF Early Career Investigators awards symposium
- Incremental Shuttle Walk Test predicts survival in non-Group 1 Pulmonary Hypertension without a ceiling effect. Pulmonary hypertension
- Incremental shuttle walking test distance is reduced in patients with pulmonary hypertension in WHO Functional Class I. Pulmonary hypertension
- Vascular Smooth Muscle Derived TRAIL is Required for Development of Pulmonary Arterial Hypertension in Sugen 5416 / Hypoxia Mice. CIRCULATION, Vol. 138
- Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre. Pulmonary Circulation and Pulmonary Vascular Disease
- P183 Impact of patient choice on survival in patients with chronic thromboembolic pulmonary hypertension offered pulmonary endarterectomy. Pulmonary vascular disease: monitoring and managing
- S111 Altered neutrophil phenotypes in pulmonary arterial hypertension. Advances in understanding chronic thrombo-embolic disease and pulmonary hypertension
- P180 Managing pregnancy in pulmonary hypertension using a multi-professional approach: a 16-year experience in a specialist referral centre. Pulmonary vascular disease: monitoring and managing
- S104 Hypoxia preconditions the innate immune response to acute bacterial pulmonary infections. Thorax, Vol. 71(Suppl 3) (pp A61.2-A62)
- S87 Deficiency of toll-like receptor 3 (TLR3) exacerbates pulmonary hypertension in mice. Thorax, Vol. 71(Suppl 3) (pp A50.1-A50)
- P28 Chronic thromboembolic pulmonary hypertension: long term outcomes in surgical and non-surgical patients. Thorax, Vol. 71(Suppl 3) (pp A98.1-A98)
- Deficiency Of Toll-Like Receptor 3 (tlr3) Exacerbates Pulmonary Hypertension In Mice. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 193
- Increased Reactive Oxygen Species Generation In Quiescent And Activated Peripheral Blood Neutrophils In Chronic Obstructive Pulmonary Disease. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 191
- HYPOXIA INDUCES HYPOTHERMIA AND SICKNESS BEHAVIOUR IN MICE FOLLOWING SUBCUTANEOUS INJECTION OF LIVE STAPHYLOCOCCUS AUREUS. THORAX, Vol. 68 (pp A140-A140)
- Differential Regulation Of Neutrophil (pmn) Survival By The Prolyl Hydroxylase Enzymes Phd2 And Phd3. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Vol. 187
- HYPOXIA-INDUCIBLE FACTOR 2 alpha REGULATES NEUTROPHILIC INFLAMMATION IN HUMANS, MICE AND ZEBRAFISH. THORAX, Vol. 67 (pp A1-A1)
- Elucidating The Mechanism By Which Monocytes Can Inhibit Hypoxic PA-SMC Proliferation. D33. ASTHMA PATHOGENESIS
- HIF-2± Regulates Neutrophilic Inflammation In Humans, Mice And Zebrafish. C31. REGULATION OF LUNG INFLAMMATION
- The natriuretic response on acute ascent to high altitude. THORAX, Vol. 62 (pp A84-A84)
- High altitude exposure causes a reduction in PFA-100 (TM) closure time in humans: evidence of platelet activation or a result of increased haematocrit?. BRITISH JOURNAL OF HAEMATOLOGY, Vol. 133 (pp 49-50)
- Impaired xenon gas transfer observed one year after hospitalisation due to COVID-19 in patients with signs of interstitial lung disease.. ISMRM Annual Meeting, 3 June 2023 - 8 June 2023.
Preprints
- Health-related quality of life in pulmonary arterial hypertension trials: a review and conceptual map, Cold Spring Harbor Laboratory.
- Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease after COVID-19 hospitalisation, Research Square Platform LLC.
- One year health outcomes associated with systemic corticosteroids for COVID-19: a longitudinal cohort study, Cold Spring Harbor Laboratory.
- Pulmonary Hypertension: Intensification and Personalisation of Combination Rx (PHoenix): A phase IV randomised trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies, Cold Spring Harbor Laboratory.
- A Mendelian randomization study with clinical follow-up links metabolites to risk and severity of pulmonary arterial hypertension, Cold Spring Harbor Laboratory.
- Large scale phenotyping of long COVID inflammation reveals mechanistic subtypes of disease, Cold Spring Harbor Laboratory.
- Cohort Profile: Post-hospitalisation COVID-19 study (PHOSP-COVID), Cold Spring Harbor Laboratory.
- Remote evaluation of risk and physiological response to therapeutic escalation and clinical worsening in patients with pulmonary hypertension, Cold Spring Harbor Laboratory.
- The effects of sleep disturbance on dyspnoea and impaired lung function following COVID-19 hospitalisation: a prospective multi-centre cohort study, Cold Spring Harbor Laboratory.
- Non-generalizability of biomarkers for mortality in SARS-CoV-2: a meta-analyses series, Cold Spring Harbor Laboratory.
- Nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination, Cold Spring Harbor Laboratory.
- Enhanced neutrophil extracellular trap formation in COVID-19 is inhibited by the PKC inhibitor ruboxistaurin, medRxiv.
- Endogenous Retroviral Elements Generate Pathologic Neutrophils and Elastase Rich Exosomes in Pulmonary Arterial Hypertension, bioRxiv.
- Interstitial lung damage following COVID-19 hospitalisation: an interim analysis of the UKILD Post-COVID study, Cold Spring Harbor Laboratory.
- First genotype-phenotype study in TBX4 syndrome: gain-of-function mutations causative for lung disease, Cold Spring Harbor Laboratory.
- The Investigation of Pulmonary Abnormalities using Hyperpolarised Xenon Magnetic Resonance Imaging in Patients with Long-COVID, Cold Spring Harbor Laboratory.
- Longitudinal lung function assessment of patients hospitalised with COVID-19 using 1H and 129Xe lung MRI, Cold Spring Harbor Laboratory.